PET/MRI and Novel Targets for Breast Cancer
Breast cancer, with its global prevalence and impact on women’s health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucia...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/1/172 |
| _version_ | 1797340108896075776 |
|---|---|
| author | Hyun Woo Chung Kyoung Sik Park Ilhan Lim Woo Chul Noh Young Bum Yoo Sang Eun Nam Young So Eun Jeong Lee |
| author_facet | Hyun Woo Chung Kyoung Sik Park Ilhan Lim Woo Chul Noh Young Bum Yoo Sang Eun Nam Young So Eun Jeong Lee |
| author_sort | Hyun Woo Chung |
| collection | DOAJ |
| description | Breast cancer, with its global prevalence and impact on women’s health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucial roles in local-regional assessment, while bone scintigraphy and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) aid in evaluating distant metastasis. Despite the proven utility of <sup>18</sup>F-FDG PET/CT in various cancers, its limitations in breast cancer, such as high false-negative rates for small and low-grade tumors, have driven exploration into novel targets for PET radiotracers, including estrogen receptor, human epidermal growth factor receptor-2, fibroblast activation protein, and hypoxia. The advent of PET/MRI, which combines metabolic PET information with high anatomical detail from MRI, has emerged as a promising tool for breast cancer diagnosis, staging, treatment response assessment, and restaging. Technical advancements including the integration of PET and MRI, considerations in patient preparation, and optimized imaging protocols contribute to the success of dedicated breast and whole-body PET/MRI. This comprehensive review offers the current technical aspects and clinical applications of PET/MRI for breast cancer. Additionally, novel targets in breast cancer for PET radiotracers beyond glucose metabolism are explored. |
| first_indexed | 2024-03-08T09:57:17Z |
| format | Article |
| id | doaj.art-d744e667a2dc4030be2c291f6fbcdcfa |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-08T09:57:17Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-d744e667a2dc4030be2c291f6fbcdcfa2024-01-29T13:47:42ZengMDPI AGBiomedicines2227-90592024-01-0112117210.3390/biomedicines12010172PET/MRI and Novel Targets for Breast CancerHyun Woo Chung0Kyoung Sik Park1Ilhan Lim2Woo Chul Noh3Young Bum Yoo4Sang Eun Nam5Young So6Eun Jeong Lee7Department of Nuclear Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 07812, Republic of KoreaDepartment of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Nuclear Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Republic of KoreaDepartment of Nuclear Medicine, Seoul Medical Center, 156 Sinnae-ro, Jungnang-gu, Seoul 02053, Republic of KoreaBreast cancer, with its global prevalence and impact on women’s health, necessitates effective early detection and accurate staging for optimal patient outcomes. Traditional imaging modalities such as mammography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging (MRI) play crucial roles in local-regional assessment, while bone scintigraphy and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) aid in evaluating distant metastasis. Despite the proven utility of <sup>18</sup>F-FDG PET/CT in various cancers, its limitations in breast cancer, such as high false-negative rates for small and low-grade tumors, have driven exploration into novel targets for PET radiotracers, including estrogen receptor, human epidermal growth factor receptor-2, fibroblast activation protein, and hypoxia. The advent of PET/MRI, which combines metabolic PET information with high anatomical detail from MRI, has emerged as a promising tool for breast cancer diagnosis, staging, treatment response assessment, and restaging. Technical advancements including the integration of PET and MRI, considerations in patient preparation, and optimized imaging protocols contribute to the success of dedicated breast and whole-body PET/MRI. This comprehensive review offers the current technical aspects and clinical applications of PET/MRI for breast cancer. Additionally, novel targets in breast cancer for PET radiotracers beyond glucose metabolism are explored.https://www.mdpi.com/2227-9059/12/1/172breast cancerPET/MRIestrogen receptorHER2FAPIhypoxia |
| spellingShingle | Hyun Woo Chung Kyoung Sik Park Ilhan Lim Woo Chul Noh Young Bum Yoo Sang Eun Nam Young So Eun Jeong Lee PET/MRI and Novel Targets for Breast Cancer Biomedicines breast cancer PET/MRI estrogen receptor HER2 FAPI hypoxia |
| title | PET/MRI and Novel Targets for Breast Cancer |
| title_full | PET/MRI and Novel Targets for Breast Cancer |
| title_fullStr | PET/MRI and Novel Targets for Breast Cancer |
| title_full_unstemmed | PET/MRI and Novel Targets for Breast Cancer |
| title_short | PET/MRI and Novel Targets for Breast Cancer |
| title_sort | pet mri and novel targets for breast cancer |
| topic | breast cancer PET/MRI estrogen receptor HER2 FAPI hypoxia |
| url | https://www.mdpi.com/2227-9059/12/1/172 |
| work_keys_str_mv | AT hyunwoochung petmriandnoveltargetsforbreastcancer AT kyoungsikpark petmriandnoveltargetsforbreastcancer AT ilhanlim petmriandnoveltargetsforbreastcancer AT woochulnoh petmriandnoveltargetsforbreastcancer AT youngbumyoo petmriandnoveltargetsforbreastcancer AT sangeunnam petmriandnoveltargetsforbreastcancer AT youngso petmriandnoveltargetsforbreastcancer AT eunjeonglee petmriandnoveltargetsforbreastcancer |